Pending — not yet graded
“Upgraded Zydus Lifesciences to 'Buy' with a target price of ₹1,400, implying over 17.5% upside. The brokerage expects performance to improve gradually in the near to mid-term, driven by capital allocation fructifying in India BGx, US specialty business, EMEU prospects, and the potential start of US biologics CDMO business in FY27. FY27 and FY28 EPS estimates were raised.”
Nuvama Analysis’s track record: 4 graded calls · 95% CI 15–85%
Zydus LifesciencesBullishCalled 12 Aug 2026
This call hasn't reached its evaluation window yet — the HIT/MISS verdict will appear here once it's graded against real price data. Save it above to find it again from your profile.